{
  "nctId": "NCT01813357",
  "briefTitle": "Does Rosuvastatin Delay Progression of Atherosclerosis in HIV",
  "officialTitle": "Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial",
  "protocolDocument": {
    "nctId": "NCT01813357",
    "filename": "Prot_SAP_ICF_000.pdf",
    "label": "Study Protocol, Statistical Analysis Plan, and Informed Consent Form",
    "date": "2014-02-14",
    "uploadDate": "2020-08-27T00:15",
    "size": 1316381,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01813357/document/Prot_SAP_ICF_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": true
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 84,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2013-07-02",
    "completionDate": "2018-11-01",
    "primaryCompletionDate": "2018-05-17",
    "firstSubmitDate": "2012-12-09",
    "firstPostDate": "2013-03-19"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Age ≥ 18 years\n* Moderate cardiovascular disease (CVD) risk, (10-15% 10 year risk of CVD)\n* HIV positive\n* Stable combination anti-retroviral therapy (cART) with plasma HIV viral load \\<200copies/ml for ≥ 6 months\n\nExclusion Criteria:\n\n* Recommended use of lipid lowering therapy according to Australian guidelines\n* Prior use of statin, fibrate, ezetimibe within the last six months\n* Contraindication to statin use",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "100 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Progression of Carotid Intima Media Thickness",
        "description": "Carotid intima media thickness will be measured by ultrasonography and the change from baseline to week 96 calculated",
        "timeFrame": "Baseline to week 96"
      }
    ],
    "secondary": [
      {
        "measure": "Rates of Adverse Events",
        "description": "Number of participants with adverse events in total and also the number of participants with adverse events thought secondary to the study medication",
        "timeFrame": "Will be assessed every 12 weeks and formally reported at 96 weeks of followup"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 44,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:19.799Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}